{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:51:14Z","timestamp":1791175874180,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Data on ceftaroline cerebrospinal fluid (CSF) levels in children are limited. This study examined ceftaroline diffusion into CSF among children with ventriculoperitoneal shunt (VPS)-related ventriculitis and external ventricular drains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Patients received a single dose of 15\u2009mg\/kg of iv ceftaroline (maximum 600\u2009mg) over 2 hours. Simultaneous plasma and CSF samples were obtained at 3 time points to measure ceftaroline concentration: end of infusion (0 hours), and 2 and 6 hours postinfusion. The areas under the curve (AUCs) for plasma and CSF were calculated using linear interpolation of concentrations at time intervals. The CSF diffusion ratio was measured as AUC\n                      <jats:sub>CSF<\/jats:sub>\n                      \/AUC\n                      <jats:sub>plasma<\/jats:sub>\n                      . Clinical and laboratory data were reviewed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Eight children (7 months\u201316 years; median, 9 years) were included. CSF cultures yielded staphylococcal species in 6 patients. Inflammation was defined by grossly abnormal CSF parameters and\/or a C-reactive protein \u226530\u2009mg\/L. Among the 5 children meeting these criteria and with complete CSF sampling at 3 time points, the ceftaroline CSF diffusion ratio (0\u20136 hours) ranged from 1.96% to 35.39%, and the 0\u20132-hour diffusion ratio ranged from 1.47% to 21.11%. In contrast, the 2 patients with minimal inflammation and concentrations available at 2 time points demonstrated substantially lower 0\u20132-hour CSF diffusion ratios (0.68% and 0.61%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion(s):<\/jats:title>\n                    <jats:p>Ceftaroline CSF diffusion in children with VPS-related ventriculitis is variable and correlates with markers of meningeal inflammation. Prospective studies are needed to evaluate the use of ceftaroline in children with VPS infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005432","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:00:25Z","timestamp":1791172825000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Ceftaroline Diffusion Into Cerebrospinal Fluid of Children With Ventriculitis Due to Ventriculoperitoneal Shunt Infection"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-4756","authenticated-orcid":false,"given":"Nahed","family":"Abdel-Haq","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Michigan, Detroit"},{"name":"Department of Pediatrics, Central Michigan University, Mount Pleasant"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4488-7959","authenticated-orcid":false,"given":"Jamal","family":"Ameli","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Wayne State University, Detroit, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Central Michigan University, Mount Pleasant"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basim I.","family":"Asmar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Michigan, Detroit"},{"name":"Department of Pediatrics, Central Michigan University, Mount Pleasant"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"R1-20261005","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1128\/AAC.01021-08","article-title":"In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.","volume":"53","author":"Brown","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R2-20261005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.00019-10","article-title":"Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.","volume":"54","author":"Kosowska-Shick","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R3-20261005","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00149-08","article-title":"In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.","volume":"52","author":"Ge","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20261005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ijantimicag.2010.07.016","article-title":"In vitro activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).","volume":"36","author":"Saravolatz","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20261005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.01324-08","article-title":"In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20261005","doi-asserted-by":"crossref","first-page":"e1383","DOI":"10.1097\/IPC.0000000000001383","article-title":"Ceftaroline fosamil as a potential treatment for central nervous system infections in children.","volume":"32","author":"Bradley","year":"2024","journal-title":"Infect Dis Clin Pract"},{"key":"R8-20261005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2146\/ajhp130246","article-title":"Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy.","volume":"71","author":"Bucheit","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"R9-20261005","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R10-20261005","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3171\/2017.10.JNS17359","article-title":"Epidemiology of central nervous system infectious diseases: a meta-analysis and systematic review with implications for neurosurgeons worldwide.","volume":"130","author":"Robertson","year":"2019","journal-title":"J Neurosurg"},{"key":"R11-20261005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.idc.2024.07.008","article-title":"Cerebrospinal fluid shunt infections.","volume":"38","author":"Simon","year":"2024","journal-title":"Infect Dis Clin North Am"},{"key":"R12-20261005","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.wneu.2022.02.078","article-title":"Infectious complications and operative management of intrathecal baclofen pumps in the pediatric population: a systematic review and meta-analysis of 20 years of pooled experience.","volume":"163","author":"Nuru","year":"2022","journal-title":"World Neurosurg"},{"key":"R13-20261005","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 Infectious Diseases Society of America\u2019s clinical practice guidelines for healthcare-associated ventriculitis and meningitis.","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R14-20261005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00003088-200039050-00003","article-title":"Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.","volume":"39","author":"Lutsar","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R15-20261005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections.","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R18-20261005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijantimicag.2013.08.019","article-title":"Continuous versus intermittent infusion of cefepime in neurosurgical patients with post-operative intracranial infections.","volume":"43","author":"Huang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R19-20261005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/jcph.317","article-title":"Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.","volume":"54","author":"Zhao","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R20-20261005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2005.08.005","article-title":"Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children.","volume":"26","author":"Goldwater","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R21-20261005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/dky489","article-title":"Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain.","volume":"74","author":"Chauzy","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R22-20261005","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00286-13","article-title":"Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model.","volume":"57","author":"Cottagnoud","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20261005","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/AAC.00285-13","article-title":"Efficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model.","volume":"57","author":"Stucki","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20261005","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dku464","article-title":"Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis.","volume":"70","author":"Kuriakose","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R25-20261005","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R26-20261005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/sur.2014.098","article-title":"A pharmacokinetic\/pharmacodynamic analysis of ceftaroline prophylaxis in patients with external ventricular drains.","volume":"16","author":"Stein","year":"2015","journal-title":"Surg Infect (Larchmt)"},{"key":"R27-20261005","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.ijantimicag.2025.107512","article-title":"Cerebrospinal fluid concentrations of ceftaroline and ceftazidime\/avibactam in healthy volunteers: pharmacokinetics and probability of target attainment.","volume":"66","author":"W\u00f6lfl-Duchek","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"R28-20261005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.wneu.2020.01.013","article-title":"Multidrug-resistant Staphylococcus epidermidis ventriculostomy-related infection successfully treated by intravenous ceftaroline after failure of daptomycin treatment.","volume":"136","author":"Roujansky","year":"2020","journal-title":"World Neurosurg"},{"key":"R29-20261005","first-page":"336","article-title":"Ceftaroline cerebrospinal fluid penetration in the treatment of a ventriculopleural shunt infection: a case report.","volume":"25","author":"Cies","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R30-20261005","doi-asserted-by":"crossref","first-page":"e0074122","DOI":"10.1128\/aac.00741-22","article-title":"Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues.","volume":"66","author":"Helfer","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20261005","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil.","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:00:29Z","timestamp":1791172829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005432","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}